Cure Pharmaceuticals, along with its partner, the Technion-Israel Institute of Technology, will be researching cannabinoid compounds in the treatment leukemia and prostate cancer. Accumulating evidence suggests that cannabinoids possess certain anti-tumor qualities. Various studies have demonstrated the effectiveness of cannabinoids for regressing different cancer types.
There are also numerous cases of cannabis helping children suffering from rare seizure disorders. The American Academy of Pediatrics has not yet endorsed the use of cannabinoid, due to concerns over brain development.
The National Cancer Institute is also not yet singing the praises of cannabis but it is recognizing that potential benefits exist for people who live with cancer, including pain relief, stimulated appetite and improved sleep. Physicians caring for cancer patients in the United States have begun prescribing cannabis predominantly for symptom management, not as a cancer treatment.”